Dipeptidyl-Peptidase IV Inhibitor

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes compared with dipeptidyl peptidase 4 inhibitors, results of a target trial emulation study suggested.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid.

Adults with type 2 diabetes using a GLP-1 receptor agonist are less likely to develop hyperkalemia than those using a DPP-IV inhibitor, according to a study published in JAMA Internal Medicine.

Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.

Adults who initiate a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those prescribed a DPP-IV inhibitor or an SGLT2 inhibitor, according to study findings published in The BMJ.

Annual expenditures for diabetes medications more than tripled in the U.S. from 2011 to 2020, and the increase played a role in an overall rise in money spent on prescription drugs, according to study findings.

Older adults with type 2 diabetes are less likely to have a cardiovascular event if they are initially prescribed an SGLT2 inhibitor or GLP-1 receptor agonist instead of a DPP-IV inhibitor, according to findings published in Diabetes Care.

HOUSTON — SGLT2 inhibitors should be the first choice of therapy for adults with type 2 diabetes and heart failure, according to two speakers at the Association of Diabetes Care and Education Specialists annual meeting.